
|Articles|June 13, 2008
Allergan to cash in on eyelash stimulant effect of glaucoma drug
Following positive clinical trial results, Allergan, the makers of bimatoprost, are submitting a new drug application (NDA) to the US Food and Drug Administration (FDA), seeking a new indication for the prostaglandin analogue as an eyelash growth stimulant.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
3
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











